Preventing Muscle Loss on GLP-1s: What the Research Supports

GLP-1 medications like semaglutide and tirzepatide drive some of the largest non-surgical weight loss ever recorded in trials, but a chunk of what comes off is not fat. Across the major studies, roughly a quarter to a third of the total weight lost is lean mass, the category that includes skeletal muscle. This guide walks through what the research actually shows about muscle loss on these drugs, which strategies have evidence behind them, and how to think about the trade-offs honestly.

Why GLP-1s Cause Muscle Loss in the First Place

Any time you lose weight, you lose some lean mass along with fat. This is true for diets, bariatric surgery, and exercise programs. The body sheds tissue it no longer needs to carry the lower weight, and some of that tissue is muscle. So muscle loss on GLP-1 drugs is not a unique side effect of the medication itself. It is mostly a consequence of fast, large-scale weight loss.

That said, a few features of GLP-1 therapy make the question worth taking seriously.

The first is appetite suppression. GLP-1 receptor agonists work largely by reducing hunger and food intake. When people eat much less, they often cut protein along with everything else. Protein is the raw material the body uses to maintain muscle. Low intake plus a calorie deficit is the exact combination that accelerates muscle breakdown.

The second is speed and magnitude. These drugs produce weight loss that is faster and deeper than most lifestyle programs. The faster the loss, the harder it is for the body to spare muscle.

The third is the patient population. Many people on GLP-1s are middle-aged or older, and muscle loss matters more as you age. Older adults already lose muscle naturally, a process called sarcopenia, and stacking drug-driven loss on top of that can affect strength, balance, and metabolic health.

There is also an open question about whether GLP-1 receptor agonists do anything to muscle beyond what weight loss alone causes. GLP-1 receptors are not heavily expressed in skeletal muscle, so a direct muscle-wasting effect from the drug seems unlikely on its face. Some early animal work has hinted at unexpected effects on muscle, but those findings are preliminary and have not been confirmed in humans. For now, the most defensible interpretation is that the muscle loss seen in trials is driven by the energy deficit and reduced food intake the drugs produce, not by the molecule attacking muscle directly. That distinction matters, because it means the levers that protect muscle during any weight loss should work here too.

What "lean mass" actually measures

One honest caveat before the numbers: most trials measure "lean body mass," not muscle directly. Lean mass includes muscle, but also water, organ tissue, connective tissue, and glycogen stores. When you lose weight, you also shed water and glycogen, and your organs can shrink slightly. So a drop in lean mass overstates the true loss of contractile muscle. The headline percentages below are real, but the muscle-specific portion is smaller than the lean-mass figure suggests.

What the Research Actually Shows

Here is where the evidence is strongest. The two largest body-composition datasets come from substudies of the pivotal semaglutide and tirzepatide trials, where participants got DEXA scans to break weight loss into fat and lean components.

Drug / Trial	Total weight change	Fat mass change	Lean mass change	Share of weight loss that was lean mass
Semaglutide 2.4 mg (STEP 1 substudy)	−15.0%	−19.3%	−9.7%	~40%
Tirzepatide (SURMOUNT-1 substudy)	−21.3%	−33.9%	−10.9%	~25%
Placebo (SURMOUNT-1 substudy)	−5.3%	−8.2%	−2.6%	~25%

A few things stand out. In the STEP 1 semaglutide substudy, total lean body mass dropped about 9.7% from baseline, and lean mass made up close to 40% of the total weight lost. In the SURMOUNT-1 tirzepatide substudy, lean mass dropped about 10.9%, but because fat loss was so much larger, lean mass was only about a quarter of the total weight lost.

That last point matters. The placebo group in SURMOUNT-1 lost about 25% of its weight as lean mass too. In other words, the ratio of lean-to-total loss with tirzepatide looked similar to what happens with ordinary calorie-restricted weight loss. The drug did not seem to make the lean-mass fraction worse than diet alone would. The SURMOUNT-1 analysis also reported that this roughly three-to-one fat-to-lean split held steady across subgroups split by age, sex, and how much weight people lost. That consistency is reassuring: it argues against the idea that certain people get a much worse muscle-loss penalty from the drug.

There is also a body-composition silver lining. In STEP 1, even though absolute lean mass fell, the proportion of lean mass relative to total body weight increased by about 3 percentage points. People ended up leaner overall, with a better ratio of muscle to fat, because they lost so much more fat than muscle. This is not a trick of statistics. If you carry far less fat and only slightly less muscle, your body composition has genuinely improved, and the metabolic markers that track with excess fat, such as blood pressure, blood sugar, and inflammatory measures, tend to improve alongside it.

Why do the two drugs differ in the lean-mass fraction? The likely answer is simply the depth of fat loss. Tirzepatide drove much larger total and fat-mass reductions in its substudy, so even though its absolute lean-mass loss was a bit higher in kilograms, that loss was diluted by a far bigger pool of fat loss. Semaglutide produced less total loss in STEP 1, so lean mass made up a larger slice of a smaller pie. The comparison is not head-to-head, the substudies used different populations and timelines, so reading a clean "tirzepatide is better for muscle" verdict into these numbers would overstate what the data can support.

The honest grade on the evidence

It is tempting to read these numbers as either "GLP-1s melt your muscle" or "muscle loss is no big deal." Neither is right.

What is well established: GLP-1 drugs cause meaningful absolute loss of lean mass, in the range of 8% to 11% of baseline lean mass in the substudies, and lean mass accounts for somewhere between a quarter and 40% of total weight lost depending on the drug and trial.

What is much less certain: whether that lean-mass loss translates into worse strength, worse function, or worse long-term health for the average person. Most trials measured body composition by scan, not muscle strength or physical performance. The studies that did look at function are small and short. We genuinely do not yet know how much the muscle loss matters for a healthy 45-year-old versus a frail 78-year-old. So the strength of the concern depends heavily on who you are.

Strategies With Evidence Behind Them

The good news is that the two interventions most likely to protect muscle during weight loss are cheap, well studied, and available to everyone. Neither is specific to GLP-1 drugs, but the biology that makes them work during ordinary dieting applies here too.

Resistance training

Lifting weights, or any progressive resistance exercise, is the single best-supported strategy for preserving muscle during weight loss. The principle is simple: muscle responds to demand. If you keep loading it, the body has a strong reason not to break it down, even in a calorie deficit.

Multiple randomized trials and meta-analyses in ordinary (non-GLP-1) weight loss have shown that adding resistance training preserves more lean mass than dieting alone, and in some cases lets people gain a little muscle while still losing fat. The signal is consistent across age groups.

The catch: most of this evidence comes from people losing weight through diet, not through GLP-1 drugs. Trials testing resistance training specifically alongside semaglutide or tirzepatide are still in progress as of 2026, with several randomized studies enrolling participants on tirzepatide and assigning some to structured resistance programs. The biological case is strong, but the drug-specific proof is not in yet. The honest read: this is your best bet, and the downside is essentially zero, but call it "very likely to help" rather than "proven in GLP-1 users."

What does a useful program look like? You do not need to become a bodybuilder. The evidence in weight-loss settings generally involves two to three sessions per week hitting the major muscle groups, with enough load that the last few repetitions are genuinely hard. Progressive overload, meaning you gradually add weight or repetitions as you get stronger, is the part that signals the body to keep its muscle. Bodyweight movements, resistance bands, and machines all count. Walking and other cardio are good for the heart and for total energy expenditure, but they do not send the same "keep this muscle" signal that resistance work does, so cardio is a complement, not a substitute.

Adequate protein intake

Protein is the second pillar. In ordinary weight-loss research, higher protein intake consistently protects lean mass. The rough threshold that keeps showing up in the literature: intakes below about 1.0 g/kg of body weight per day are linked to more muscle loss, while intakes in the 1.2 to 1.6 g/kg range better preserve lean mass during a deficit.

For a 90 kg person, that 1.2 to 1.6 g/kg range works out to roughly 108 to 144 grams of protein a day. That sounds like a lot, and on a GLP-1 drug it is genuinely hard to hit, because appetite suppression makes eating any volume of food a chore. This is the real-world rub: the people who most need the protein are the ones least able to eat it.

Practical workarounds that people use: eating protein first at each meal, leaning on dense sources like Greek yogurt, eggs, lean meat, and protein shakes, and spreading intake across the day rather than cramming it into one meal. Spreading matters because the body can only use so much protein for muscle maintenance in one sitting, so three or four moderate doses tend to beat one large one. A scoop of whey or a ready-to-drink shake delivers 20 to 30 grams in a few ounces of liquid, which is far easier to get down than the equivalent in chicken breast when your appetite is gone.

It is also worth being clear about what protein does and does not do. Eating more protein on its own, without any resistance training, modestly protects lean mass but will not rebuild meaningful muscle. The two strategies work best together: training creates the demand, and protein supplies the building blocks. Skipping either one leaves results on the table. A few individual trials have even found that extra protein above habitual intake did little for lean mass without exercise, which underlines the point that protein is a partner to training, not a replacement for it.

Strategy	Strength of evidence	Evidence specifically in GLP-1 users?	Effort
Resistance training	Strong (general weight loss)	Trials ongoing, not yet conclusive	High
Protein 1.2–1.6 g/kg/day	Strong (general weight loss)	Limited	Moderate, hard with low appetite
Slower dose titration	Mechanistically plausible	Weak	Low
Adequate calories (avoid extreme deficit)	Moderate	Weak	Low
Muscle-targeted drugs (e.g., bimagrumab)	Promising early trial	Phase 2 only	N/A (not approved)

Dose titration and avoiding an extreme deficit

Two lower-effort habits round out the picture. The first is sensible dose titration. GLP-1 drugs are meant to be increased slowly over weeks or months. Rushing to a high dose can crush appetite so hard that food intake collapses, which deepens the deficit and the muscle loss along with it. Staying at the lowest dose that gives good results, rather than the maximum dose, can keep eating closer to a level where protein targets are reachable. The evidence here is more mechanistic than proven, but it costs nothing and aligns with how the drugs are designed to be used.

The second is simply not starving. Appetite suppression makes it easy to drift into a very large calorie deficit without noticing, sometimes well below what the body needs even for substantial fat loss. Extreme deficits accelerate muscle breakdown. The aim is steady, sustainable loss, not the fastest possible drop on the scale. A registered dietitian can help set a floor for daily calories and protein so the deficit stays in a productive range.

Newer and Experimental Approaches

A handful of drug strategies aim to attack muscle loss directly rather than relying on diet and exercise.

The most discussed is bimagrumab, an antibody that blocks a receptor involved in limiting muscle growth. In a Phase 2 trial pairing bimagrumab with semaglutide, the combination produced large weight loss where the overwhelming majority of weight lost came from fat, with lean mass largely preserved. Reported figures put the combination at around 22% total weight loss at 72 weeks, with about 92% of that loss coming from fat mass, versus roughly 76% fat in the semaglutide-alone arm. The combination held lean-mass loss to under 3%, compared with around 7% for semaglutide alone.

Those results are genuinely striking, but keep the grade honest: this is a single Phase 2 trial. Bimagrumab is not approved for this use, longer-term safety is not established, and the data have not been replicated at Phase 3 scale. It is a promising research direction, not a treatment you can get today.

It is also worth understanding what bimagrumab represents conceptually. Rather than slowing fat loss to spare muscle, it actively shifts where weight comes off, pushing the body to give up fat while shielding or even adding muscle. That is a different strategy from diet and exercise, which protect existing muscle but do not redirect the loss. If muscle-sparing drugs eventually reach approval, the calculus around GLP-1 muscle loss could change substantially. But "eventually" is doing real work in that sentence, and nothing on the market today offers this benefit in a proven, regulated form.

Other muscle-targeting compounds and various peptides are marketed online with claims about preserving or building muscle. The evidence for those in the context of GLP-1 weight loss is thin to nonexistent, and product quality in the gray market is a real concern. Unregulated peptides sold for "muscle preservation" have not been tested in the trials that would justify the claims, and dosing, purity, and contamination are unknowns. If you are considering anything beyond food and exercise, that decision belongs with a clinician, not a vendor's sales page.

Who Should Worry, and Who Shouldn't Much

This is where personalizing the risk matters more than any single statistic.

Higher concern: older adults, especially those over 65, and anyone who already has low muscle mass, frailty, a history of falls, or osteoporosis. For this group, muscle and bone are already declining, and rapid weight loss can push someone toward sarcopenia or raise fracture risk. The research community has flagged GLP-1 use in people at high risk for sarcopenia as something that warrants active monitoring, including attention to strength and physical function, not just the number on the scale.

Bone is part of this conversation too. Rapid, large weight loss can reduce bone mineral density, and older adults who already have thinning bones are most exposed. The loss of muscle and the loss of bone tend to travel together, since strong muscles load and stimulate the skeleton. That is one more reason resistance training earns its place at the top of the list: it supports bone as well as muscle. For higher-risk patients, a clinician may reasonably want baseline and follow-up measures of body composition or bone density, plus attention to vitamin D and calcium.

A reasonable monitoring approach for anyone in the higher-concern group: track grip strength or how easily you rise from a chair, watch for new unsteadiness or fatigue, and flag any of those to your clinician rather than assuming they are just part of losing weight. Function is the thing that actually matters, and it is something you can notice without a lab.

Lower concern: younger and middle-aged adults with substantial fat to lose and reasonable baseline muscle. For this group, the absolute lean-mass loss is real but the functional consequences appear modest, especially if they are doing resistance training and eating enough protein. The improvement in fat-to-muscle ratio and the metabolic benefits of losing significant fat generally outweigh the muscle cost.

For everyone, two simple habits move the needle: do not crash through the deficit by skipping meals on top of the appetite suppression, and do at least some resistance work. The goal is not to avoid all muscle loss, which is impossible during major weight loss, but to keep it in the normal range while you shed fat.

How This Fits With Peptide Therapy More Broadly

Many people exploring GLP-1 drugs also look into other peptides marketed for body composition, recovery, or growth hormone support. It is worth keeping the evidence bar consistent. The GLP-1 muscle-loss question has large randomized trials behind it. Most other peptides marketed for muscle do not. If you are building a plan, anchor it on the things that are proven: enough protein, progressive resistance training, and a sensible rate of weight loss. Layer experimental compounds on top only with a clinician's guidance and clear eyes about what is and isn't established.

For deeper background, see our overview of semaglutide's mechanism of action, our comparison of tirzepatide versus retatrutide, and our guides to growth hormone peptides like sermorelin and ipamorelin and tesamorelin versus CJC-1295 for body composition. If you are weighing whether the compounded versions of these drugs are appropriate, our review of compounded GLP-1 peptides' legal and safety status covers the trade-offs.

Frequently Asked Questions

How much muscle do you actually lose on Ozempic or Mounjaro?

In the body-composition substudies, total lean body mass dropped roughly 9% to 11% from baseline, and lean mass made up about a quarter to 40% of total weight lost, depending on the drug. But "lean mass" includes water, glycogen, and organ tissue, not just muscle, so the true muscle loss is somewhat smaller than those figures suggest.

Is muscle loss on GLP-1s worse than with regular dieting?

Not clearly. In the SURMOUNT-1 tirzepatide substudy, the share of weight lost as lean mass (about 25%) was nearly identical to the placebo group losing weight through lifestyle alone (about 25%). The drug produces more total loss, so the absolute muscle loss is larger, but the proportion looks similar to ordinary weight loss.

Will lifting weights stop muscle loss on a GLP-1?

Resistance training is the best-supported way to preserve muscle during weight loss in general research, and the biology applies here. But trials testing it specifically alongside GLP-1 drugs are still ongoing as of 2026, so it is best described as very likely to help rather than proven in this exact setting. The downside is essentially zero, so it is worth doing.

How much protein should I eat on a GLP-1 medication?

General weight-loss research supports roughly 1.2 to 1.6 grams of protein per kilogram of body weight per day to preserve lean mass. For many people that is 100 to 150 grams daily, which is hard to reach when appetite is suppressed. Prioritizing protein at each meal and using shakes or dense sources helps.

Should older adults avoid GLP-1 drugs because of muscle loss?

Not necessarily, but the risk-benefit calculation is different. Older adults, especially those who are already frail or have low muscle mass, face a higher chance of meaningful functional decline. This group should use these drugs with closer monitoring of strength and function, a strong emphasis on protein and resistance training, and a clinician guiding the decision.

---

This article is for educational purposes only and is not medical advice. Discuss any medication, supplement, or exercise change with a qualified healthcare provider.

References

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM, 2021 (STEP 1 trial, PMID 33567185)
• Wilding JPH, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study (PMC8089287)
• Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab, 2025 (PMID 39996356)
• GLP-1 receptor agonist therapy in patients at high risk for sarcopenia. Current Nutrition Reports, 2025 (PMID 40289060)
• Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine (BELIEVE trial)
• PubMed: protein intake and lean mass preservation during weight loss (systematic reviews and meta-analyses)
• PubMed: resistance training and lean mass preservation during weight loss (meta-analyses)